Michael Powell, Director at Trius Therapeutics Inc (TSRX), sold 6,900 shares at $5.56 ($39K) on 2012-01-18, disclosed to the SEC on 2012-01-20.
Scheduled sale ($39k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.56 | 4,300 | $24K | 62.0% |
| 2 | $5.64 | 2,600 | $15K | 38.0% |
| Total | $5.59 avg | 6,900 | $39K | 100% |
| Filing → |
| OCRX | SELL | 2016-12-30 | $15K | — | Filing → |
| MIRN | BUY | 2015-10-06 | $6.0M | — | Filing → |
| AERI | SELL | 2014-07-11 | $24.2M | — | Filing → |